Most Read

Based in San Diego, VelosBio is involved in the development of first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VLS-101, the company’s investigational antibody-drug conjugate

The EU approval of Forxiga was based on data from the international, multi-centre, parallel-group, randomised and double-blinded DAPA-HF phase III trial. AstraZeneca claims that Forxiga is the first

Based in Mumbai, IQGEN-X provides niche and complex drug development technologies for the pharmaceutical industry. IQGENX was founded in October 2016 to provide advanced research and technology for

Deucravacitinib, a novel, oral and selective tyrosine kinase 2 (TYK2) inhibitor, is being assessed in clinical studies across multiple immune-mediated diseases such as psoriasis, psoriatic arthritis, lupus and

Clover will use the funding to conduct the global pivotal phase 2/3 efficacy clinical trial of the protein-based S-Trimer Covid-19 vaccine candidate. It will also use the funds

The deal has a total enterprise value of around $368m. Based in Cambridge, Horizon Discovery offers CRISPR and RNAi reagents, cell models, cell engineering and base editing solutions

Adakveo can be provided as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate, said Novartis. Adakveo attaches to

Under the deal, Cheplapharm will purchase Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide), which is marketed in around 70 countries across

Under the deal, Vedere shareholders have secured $150m upfront payment and also eligible to secure up to $130m in milestone payments. Vedere Bio has an advanced platform for